# EDGAR Filing Document

**Accession Number:** 0001389545
**File Stem:** 0001398344-25-019284
**Filing Date:** 2025-10
**Character Count:** 17641
**Document Hash:** a0f5f506e6b24b60814d61285c5fb0a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001398344-25-019284.hdr.sgml**: 20251017

**ACCESSION NUMBER**: 0001398344-25-019284

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251017

**DATE AS OF CHANGE**: 20251017

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NovaBay Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001389545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 680454536
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-83670
- **FILM NUMBER:** 251401511

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 POWELL STREET, SUITE 1150
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** (510) 899-8800

**MAIL ADDRESS:**
- **STREET 1:** 2000 POWELL STREET, SUITE 1150
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** POPLAR POINT CAPITAL MANAGEMENT LLC
- **CENTRAL INDEX KEY:** 0001588273

**ORGANIZATION NAME:**
- **EIN:** 460530967
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 330 PRIMROSE ROAD, SUITE 400
- **CITY:** BURLINGAME
- **STATE:** CA
- **ZIP:** 94010
- **BUSINESS PHONE:** 650-239-9049

**MAIL ADDRESS:**
- **STREET 1:** 330 PRIMROSE ROAD, SUITE 400
- **CITY:** BURLINGAME
- **STATE:** CA
- **ZIP:** 94010

## Exhibit 99.1

**IRREVOCABLE NOTICE OF TERMINATION OF**

**VOTING AGREEMENT**

Poplar Point Capital Management LLC

Poplar Point Capital Partners LP

Poplar Point Capital GP LLC

Mr. Jad Fakhry

Address: 330 Primrose Road, Suite 400

Burlingame, CA 94010

Attention: Mr. Jad Fakhry

E-mail: jad@poplarpointcapital.com

Mr. David Elliot Lazar

30B, Tower 200 The Towers,

Winston Churchill, San Francisco, Paitilla,

Panama City, Panama. 07196

E-mail: david@activistinvestingllc.com

This Irrevocable Notice of Termination (this "**Notice**") of the Voting Agreement, dated as of August 19, 2025 (the "**Voting Agreement**"), by and among (a) NovaBay Pharmaceuticals, Inc., a Delaware corporation whose Common Stock is listed for trading on the NYSE American (the "**Company**"), (b) Mr. David Elliot Lazar, an individual ("**Lazar**"), and (c) each of (i) Mr. Jad Fakhry, an individual, (ii) Poplar Point Capital Management LLC, a Delaware limited liability company, (iii) Poplar Point Capital Partners LP, a Delaware limited partnership, and (iv) Poplar Point Capital GP LLC, a Delaware limited liability company (each person or entity part of group "(c)" hereinafter referred to as a "**Stockholder**" and, collectively, the "**Stockholders**"), is given as of this 16th day of October, 2025 by the Company. Capitalized terms used herein and not defined shall have the meaning set forth in the Voting Agreement.

WHEREAS, the Voting Agreement provides that the term of the Voting Agreement shall commence on the Signature Date and continue for a period of two (2) years from the Proxy Effective Date, unless terminated by the Company, in the Company's sole discretion;

WHEREAS, the Stockholders have requested that they have the ability to sell or otherwise transfer all or a portion of the Proxy Shares in the open market or otherwise once the Approval has been received, which various terms of the Voting Agreement would limit or otherwise interfere with; and

WHEREAS, to allow for such transferability of the Proxy Shares after the Approval, the Company has determined that it shall terminate the Voting Agreement in full, with such termination conditioned solely upon, and effective immediately after, the Approval.

NOW, THEREFORE, pursuant to its rights and powers under Section 10 of the Voting Agreement, the Company hereby provides irrevocable notice of the termination of the Voting Agreement, with such termination conditioned solely upon, and effective immediately after, the Approval. Upon termination pursuant to this Notice, the Voting Agreement shall cease to be in effect and all rights and obligations thereunder, including all grants of proxy, shall terminate in full, effective simultaneously therewith, and all legends on Proxy Shares with respect thereto shall no longer be required and thereafter promptly removed. Neither this Notice nor the termination of the Voting Agreement may be revoked, modified or amended without the prior written consent of all parties to the Voting Agreement. This Notice and all acts and transactions pursuant hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. The other parties to the Voting Agreement are intended third party beneficiaries of this Notice.

Intending to be bound hereby, the Company has executed this Notice as of the date first written above.

---

| | |
|:---|:---|
| **NovaBay Pharmaceuticals, Inc.** | **NovaBay Pharmaceuticals, Inc.** |
| By: | /s/ David Lazar |
| Name: | David Lazar |
| Title: | CEO |

---

cc:

Abby Brown (abby.brown@squirepb.com)

Ben Fackler (Ben.Fackler@arnoldporter.com)

Daniel Fligsten (dan@fligstenlawgroup.com)

Mr. Avraham Ben-Tzvi (abz@abz-law.com)

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Novabay Pharmaceuticals, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**66987P409**

*(CUSIP Number)*

**Jad Fakhry**<br>330 Primrose Road<br>Suite 400<br>Burlingame CA 94010<br>650-239-9049

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/15/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **66987P409** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Poplar Point Capital Management LLC** | Name of reporting person<br>**Poplar Point Capital Management LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1020300.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1020300.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.52%** | Percent of class represented by amount in Row (11)<br>**17.52%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **66987P409** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Poplar Point Capital Partners LP** | Name of reporting person<br>**Poplar Point Capital Partners LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1020300.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1020300.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.52%** | Percent of class represented by amount in Row (11)<br>**17.52%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **66987P409** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Poplar Point Capital GP LLC** | Name of reporting person<br>**Poplar Point Capital GP LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1020300.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1020300.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.52%** | Percent of class represented by amount in Row (11)<br>**17.52%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

| **CUSIP No.** | **66987P409** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jad Fakhry** | Name of reporting person<br>**Jad Fakhry** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1020300.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1020300.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | Aggregate amount beneficially owned by each reporting person<br>**1020300.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.52%** | Percent of class represented by amount in Row (11)<br>**17.52%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
Novabay Pharmaceuticals, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2000 Powell Street, Suite 1150, Emeryville, CA, 94608

This Amendment is being filed as disclosure to the effect that Novabay Pharmaceuticals, Inc. terminated the voting agreement effective upon the vote.  No other Items noted herein have been updated since previous filed Amendment.

Irrevocable Notice of Termination of Voting Agreement included as Exhibit to this filing.

**Item 4. Purpose of Transaction**

The purpose of the acquisition of the Common Stock is for investment, and the acquisitions of the Common Stock were made in the ordinary course of business.  Given the Reporting Persons' ownership percentage of the Issuer, the Reporting Persons holding of the Common Stock may have the purpose or effect of control.

At this time, the Reporting Persons have no specific plan or proposal to acquire additional Common Stock or dispose of the Common Stock.

**Item 5. Interest in Securities of the Issuer**

**(a)**
(i) PPCM
1,020,300
17.52%

(ii) PPCP
1,020,300
17.52%

(iii) PPCGP
1,020,300
17.52%

(iv) Jad Fakhry
1,020,300
17.52%

**(b)**
(i) PPCM
Sole Voting Power - 0
Shared Voting Power - 1,020,300
Sole Dispositive Power - 0
Shared Dispositive Power - 1,020,300

(ii) PPCP
Sole Voting Power - 0
Shared Voting Power - 1,020,300
Sole Dispositive Power - 0
Shared Dispositive Power - 1,020,300

(iii) PPCGP
Sole Voting Power - 0
Shared Voting Power - 1,020,300
Sole Dispositive Power - 0
Shared Dispositive Power - 1,020,300

(iv) Jad Fakhry
Sole Voting Power - 0
Shared Voting Power - 1,020,300
Sole Dispositive Power - 0
Shared Dispositive Power - 1,020,300

**(c)**
In the past 60 days, the following transactions were effected by the Reporting Persons, in normal course of business:
Not applicable.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Other than as described in this Statement, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Poplar Point Capital Management LLC

**Signature:** /s/ Jad Fakry

**Name/Title:** Jad Fakhry, Manager

**Date:** 10/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Poplar Point Capital Partners LP

**Signature:** /s/ Jad Fakry

**Name/Title:** Jad Fakhry, Manager

**Date:** 10/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Poplar Point Capital GP LLC

**Signature:** /s/ Jad Fakry

**Name/Title:** Jad Fakhry, Manager

**Date:** 10/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jad Fakhry

**Signature:** /s/ Jad Fakry

**Name/Title:** Jad Fakhry

**Date:** 10/17/2025